|
Age (years), mean ± SD
|
54.3 ± 7.6
|
|
Sex, n (%)
|
|
Man
|
117 (95.1)
|
|
Woman
|
6 (4.9)
|
|
ECOG performance status, n (%)
|
|
0
|
105 (85.4)
|
|
1
|
18 (14.6)
|
|
Pathology, n (%)
|
|
SCC
|
120 (97.6)
|
|
Adenocarcinoma
|
3 (2.4)
|
|
Location, n (%)
|
|
Upper
|
24 (19.5)
|
|
Middle
|
59 (48.0)
|
|
Lower
|
40 (32.5)
|
|
BMI (kg/m2), mean ± SD
|
22.1 ± 3.3
|
|
Histologic grade, n (%)
|
|
Grade 1
|
12 (9.8)
|
|
Grade 2
|
88 (71.5)
|
|
Grade 3
|
23 (18.7)
|
|
Smoking, n (%)
|
|
No (never smoked or quitted)
|
7 (5.7)
|
|
Yes (current smoker)
|
116 (94.3)
|
|
Clinical T stage, n (%)
|
|
cT1
|
1 (0.8)
|
|
cT2
|
36 (29.3)
|
|
cT3
|
80 (65.0)
|
|
cT4a
|
6 (4.9)
|
|
Clinical N stage, n (%)
|
|
cN0
|
14 (11.4)
|
|
cN1
|
57 (46.3)
|
|
cN2
|
39 (31.7)
|
|
cN3
|
13 (10.6)
|
|
cTNM stage, n (%)
|
|
II
|
31 (25.2)
|
|
III
|
92 (74.8)
|
|
Gross tumor volume (ml), mean ± SD
|
100.9 ± 73.2
|
|
Radiation dose (Gy), median (IQR)
|
44.0 (43.2–45.0)
|
|
40–44 Gy, n(%)
|
62 (50.4)
|
|
45–50.4 Gy, n(%)
|
61 (49.6)
|
|
Target volume (ml), mean ± SD
|
527.6 ± 228.5
|
|
Dose-volume of lunga (%), mean ± SD
|
|
V5
|
74.0 ± 21.2
|
|
V20
|
20.8 ± 6.4
|
|
Mean heart dose (Gy), mean ± SD
|
18.3 ± 7.6
|
